Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Digi Power X reported Q3 2026 revenue of $12.25 million, an 85% increase over the prior quarter, driven by a 400% surge in AI-related revenue. The company ended the period with $119.6 million in cash and digital currencies and expects to close a $200 million credit facility in Q4 2026 to fund its data center expansion.
Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.
Term
Q3 2026
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer
Lument Finance Trust reported a net loss attributable to common stockholders of $13.5 million for the third quarter of 2026, primarily driven by a $16.5 million provision for credit losses and $5.2 million in real estate owned impairment. Total assets decreased to $1.08 billion from $1.22 billion at year-end 2025, while the company executed a 1-for-10 reverse stock split in September 2026.
Twenty One Capital reported Q3 2026 financial results, highlighted by a net income of $1.087 billion primarily driven by a $1.093 billion fair-value gain on its Bitcoin holdings. The company ended the quarter with 43,514 Bitcoin and $102.8 million in cash while evaluating new business opportunities across the Bitcoin and energy ecosystems.
Term
Q3 2026
“Our mandate is clear: build a durable, cash-generating business around one of the largest corporate Bitcoin treasuries in the world. A balance sheet is not a business. It is our starting point.”
Raphael Zagury, Chief Executive Officer
“We welcome Bitcoin’s appreciation. But gains from an asset we own are not the same as earnings from businesses we operate. Building the latter is our job.”
Twenty One Capital, Inc. reported a net income of $1.09 billion for the three months ended September 30, 2026, primarily driven by a $1.09 billion gain from the change in fair value of digital assets. However, for the nine-month period, the company recorded a net loss of $186.5 million as digital asset values fluctuated, while maintaining a significant Bitcoin treasury valued at approximately $3.64 billion.
Milestone Scientific reported a net loss of approximately $2.5 million for the nine months ended September 30, 2026, an improvement from a $4.6 million loss in the prior year period. Product sales grew slightly to $7.2 million, while the company significantly reduced operating expenses, particularly in research and development and SG&A.
XTI Aerospace reported Q3 2026 revenue of $35.3 million, a 46.1% increase over proforma Q3 2025 results, driven by strong demand in its Drone Nerds business. The company achieved positive Adjusted EBITDA of $1.6 million and completed a strategic pivot by discontinuing its aircraft business and reducing corporate overhead.
Term
Q3 2026
“Our strategic pivot to focus on our Drone Nerds business is substantially complete. We have discontinued the operation of the XTI aircraft business, rightsized our corporate overhead and are focused on the significant opportunity in the commercial and enterprise drone market.”
Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
“The growth opportunities we see across our portfolio combined with continued disciplined expense management is expected to lead to the transition to positive ongoing operating cash flows during the fourth quarter of 2026.”
Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.
Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.
Term
Q3 2026
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”
Immunic, Inc. reported a net loss of $109.0 million for the nine months ended September 30, 2026, compared to $77.9 million in the prior year, driven by increased research and development and general and administrative expenses. The company significantly strengthened its liquidity, ending the period with $132.0 million in cash following a $187.3 million private placement in February 2026.
Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.
Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.
Term
Q3 2026
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi
Fathom Holdings Inc. reported a significant decline in revenue to $88.6 million for Q3 2026 compared to $115.3 million in the prior year, primarily driven by a $12.1 million impairment charge. The company's net loss widened to $21.8 million for the quarter, and total shareholders' equity decreased from $37.4 million at year-end 2025 to $1.8 million as of September 30, 2026.
QXO, Inc. reported a significant expansion in net sales to $4.9 billion for the third quarter of 2026, driven by major acquisitions including Beacon Roofing Supply and TopBuild Corp. Despite the revenue growth, the company recorded a net loss for the nine months ended September 30, 2026, as it integrated these large-scale operations and managed increased interest expenses from acquisition-related debt.
SBC Medical Group Holdings reported total revenues of $150.8 million for the nine months ended September 30, 2026, a 12.5% increase year-over-year. Net income for the same period rose to $38.9 million, driven by strong performance in related party revenues and improved operational efficiency.
PowerCompute reported Q3 2026 financial results, achieving net income of $0.4 million compared to a loss in the prior year, driven by fair value gains as Bitcoin prices rose 43%. The company significantly improved its balance sheet by reducing secured debt by 94% and announced the purchase of 600 new S21++ miners to increase hashrate by 10%.
Contango Silver & Gold Inc. reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $12.0 million loss in the prior year, driven by increased exploration and general administrative expenses. Total assets grew significantly to $492.8 million following the Dolly Varden acquisition, which added substantial mineral property and equipment value.
SBC Medical Group reported third quarter 2026 revenue of $59 million, a 35% increase year-over-year, driven by service fee revisions and clinic network expansion. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA grew 66% to $28 million. The company's supported clinic network expanded to 293 locations, representing a year-over-year increase of 36 locations.
Term
Q3 2026
“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA margin of 47%.”
Yoshiyuki Aikawa, Chairman and CEO
“Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”
Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.
Regional Health Properties reported a net loss of $2.9 million for the nine months ended September 30, 2026, compared to a net income of $0.7 million in the prior year period. While total revenues grew significantly to $70.6 million due to increased patient care and pharmacy revenues, the company faced higher operating expenses and an impairment loss on assets held for sale.
Blue Biofuels, Inc. reported a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a loss of $1,587,132 in the prior year period. The company remains in the development stage with zero revenue, while operating expenses increased due to higher research and development costs and stock-based compensation.
First Choice Healthcare Solutions reported a significant net loss of $19.1 million for the nine months ended September 30, 2026, primarily driven by $17.4 million in interest expense. The company is currently pivoting its strategy toward a network of nurse practitioner-driven primary care clinics despite having zero revenue in the current period.
OpenWorld, Inc. reported a significant net loss of $16.1 million for the nine months ended September 30, 2026, compared to a net income of $1.0 million in the prior year, primarily driven by a decrease in total revenues and a sharp increase in general and administrative expenses. The period was marked by a reverse acquisition of VerifyMe, Inc. and substantial non-cash stock-based compensation and professional fees totaling over $12 million.
Hyperion DeFi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $79.4 million compared to a net loss of $5.5 million in the prior year, primarily driven by $93.6 million in realized and unrealized gains on digital assets. Total assets grew to $146.3 million from $51.8 million at year-end 2025, reflecting substantial appreciation in the company's digital asset holdings.
King Resources Global, Inc. is a Nevada holding company operating through subsidiaries in Hong Kong and the British Virgin Islands. The company reported 112,616,649 shares of common stock outstanding as of October 21, 2026, and is currently navigating significant regulatory risks related to PRC oversight and the Holding Foreign Companies Accountable Act.
Presidio Production Company reported Q3 2026 financial results, featuring a 15% increase in net production to 26.1 MBoe/d following the acquisition of Canyon Creek. The company reported total revenue of $57.3 million and Adjusted EBITDA of $29.1 million, while declaring an increased quarterly dividend of $0.375 per share.
Term
Q3 2026
“Our third quarter results reflect continued execution of our acquisition and optimization strategy. Canyon Creek contributed its first full quarter, and our continued focus on improving the performance of our existing assets has allowed us to increase our annualized dividend to $1.50 per share. Each of these steps reinforces the acquisition model we are building to consolidate producing oil and gas assets.”
Will Ulrich, Chairman and Co-CEO
“When we closed Canyon Creek, we said the Arkoma Basin was a place to build scale through consolidation. In our first full quarter operating the assets, we moved the wells onto our production systems, right-sized compression and changed chemical vendors, and Canyon Creek helped lower our lease operating expense per Boe.”
TCW Specialty Lending IX LLC is a newly formed business development company that has not yet commenced investment operations as of September 30, 2026. The company reported total assets of $484,830, primarily consisting of receivables from its investment adviser for organizational and offering costs, with a net asset value of $1,000. All operating expenses incurred since inception have been reimbursed by the Investment Adviser, resulting in zero net investment income.
TCW Star Direct Lending LLC reported total investments at fair value of approximately $238 million as of September 30, 2026, with a portfolio primarily consisting of senior secured debt. The company maintains a diversified industry exposure, with significant concentrations in Food Products, Hotels, Restaurants & Leisure, and Personal Care Products.
TCW Specialty Lending LLC is a newly formed business development company that commenced operations on March 2, 2026. As of September 30, 2026, the company held a diversified portfolio of debt investments across various industries, with its largest exposures in Electrical Equipment (14.9% of net assets) and Building Products (12.1% of net assets).
TCW Steel City Senior Lending BDC reported total investments of $791.4 million as of September 30, 2026, with a portfolio primarily focused on debt investments across various industries including Building Products and Professional Services. The company maintains a significant position in short-term U.S. Treasury Bills and reported 19,659,875 common shares outstanding.